Molecullin Gets Patent for Annamycin Targeting Unmet Need in AML

 Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension

Next-generation anthracycline uses unique lipid-based delivery technology to bring hope to the estimated 58% of AML patients for whom no approved therapy exists

https://www.prnewswire.com/news-releases/moleculin-announces-us-patent-issue-notification-for-annamycin-targeting-unmet-need-in-aml-302100349.html